Lineage library
Lineages from clinical milestones
Each lineage starts from a verified clinical trial, FDA approval, or regulatory milestone, then traces backward through the discoveries, tools, failures, and branch points that made it possible.
Daraxonrasib for KRAS G12D-mutant pancreatic cancer
Daraxonrasib (KRAS G12D inhibitor) · Pancreatic ductal adenocarcinoma
First direct KRAS G12D inhibitor to reach efficacy testing in pancreatic ductal adenocarcinoma.
Traces backward through KRAS oncogene discovery, protein structural biology, covalent inhibitor chemistry, precursor lesion biology, and translational oncology.
Luxturna for RPE65-mediated inherited retinal disease
Voretigene neparvovec (AAV2-RPE65) · Leber congenital amaurosis type 2 (RPE65 mutation)
FDA approval of voretigene neparvovec-rzyl for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Traces backward through RPE65 biology, inherited retinal degeneration, AAV vector development, animal models, clinical translation, and subretinal delivery.
ION582 for Angelman syndrome
ION582 (obudanersen), antisense oligonucleotide · Angelman syndrome
REVEAL trial (NCT06914609) testing whether ASO-mediated UBE3A unsilencing improves developmental outcomes in children with Angelman syndrome.
Traces backward through UBE3A imprinting, antisense transcript biology, ASO chemistry, intrathecal CNS delivery, and rare-disease trial design.
BMS-986278 for idiopathic pulmonary fibrosis
BMS-986278, oral LPA1 receptor antagonist · Idiopathic pulmonary fibrosis
Phase 3 trial (NCT06003426) testing whether selective LPA1 receptor blockade slows FVC decline in IPF patients.
Traces backward through fibrosis pathology, fibroblast biology, lysophosphatidic acid signaling, LPA1 receptor pharmacology, and antifibrotic drug development.
Under investigation
Anchored to specific endpoints. Published when complete.
Semaglutide for cardiovascular risk reduction in obesity (Wegovy / SELECT)
Semaglutide 2.4 mg (Wegovy), GLP-1 receptor agonist · Cardiovascular disease in adults with obesity or overweight
FDA expanded approval of semaglutide to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, based on the SELECT trial.
Traces backward through GLP-1 discovery, incretin biology, peptide pharmacology, cardiovascular-metabolic physiology, and the SELECT cardiovascular outcomes trial.
Pembrolizumab for MSI-H/dMMR solid tumors
Pembrolizumab (anti-PD-1 monoclonal antibody) · MSI-H/dMMR solid tumors (tissue-agnostic)
FDA approval of pembrolizumab for unresectable or metastatic MSI-H/dMMR solid tumors after prior treatment, a landmark tissue-agnostic cancer approval based on a shared molecular feature rather than tumor site.
Traces backward through PD-1 biology, T-cell regulation, mismatch repair deficiency, microsatellite instability, tumor neoantigens, basket trials, and tissue-agnostic regulatory logic.
Want to suggest a trial or milestone for investigation?
lineages@triallineage.org